2023

1. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

   Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525